

Ming-Wei Wang, Ph.D.

Director, National Center for Drug Screening

Shanghai Institute of Materia Medica, Chinese Academy of Sciences

China

Title: Innovative Biopharmaceutical R&D in China—Status and Challenges

Abstract:

Innovation is the new national strategy for China's next phase of economic growth and for implementation of the "Long-term Science and Technology Development Plan" of the country. Innovation capability strengthening has been emphasized as a major strategic objective to promote domestic pharmaceutical industry restructuring and growth mode transformation. Chinese pharmaceutical sector is on the way to become a global leading powerhouse of innovation. China's demand for novel biologics has been increasing at a fast pace in the past decade. Startup biotech companies led by Chinese "overseas returnees" have built up impressive R&D capabilities for new biologics and biosimilars with a demonstrated growth potential. This talk will give a comprehensive overview on China's biopharmaceuticals infrastructure, platforms and innovation environment by highlighting the R&D status, its challenges and future trends.